CRISPR Therapeutics AG (CRSP)
46.29
-0.97
(-2.05%)
USD |
NASDAQ |
Nov 21, 16:00
46.25
-0.04
(-0.09%)
After-Hours: 20:00
CRISPR Therapeutics Enterprise Value: 2.015B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 2.015B |
| November 20, 2024 | 2.098B |
| November 19, 2024 | 2.073B |
| November 18, 2024 | 2.102B |
| November 15, 2024 | 2.097B |
| November 14, 2024 | 2.063B |
| November 13, 2024 | 2.314B |
| November 12, 2024 | 2.394B |
| November 11, 2024 | 2.747B |
| November 08, 2024 | 2.470B |
| November 07, 2024 | 2.492B |
| November 06, 2024 | 2.393B |
| November 05, 2024 | 2.363B |
| November 04, 2024 | 2.382B |
| November 01, 2024 | 2.397B |
| October 31, 2024 | 2.023B |
| October 30, 2024 | 2.154B |
| October 29, 2024 | 2.241B |
| October 28, 2024 | 2.306B |
| October 25, 2024 | 2.106B |
| October 24, 2024 | 2.156B |
| October 23, 2024 | 1.990B |
| October 22, 2024 | 2.164B |
| October 21, 2024 | 2.204B |
| October 18, 2024 | 2.239B |
| Date | Value |
|---|---|
| October 17, 2024 | 2.185B |
| October 16, 2024 | 2.246B |
| October 15, 2024 | 2.165B |
| October 14, 2024 | 2.146B |
| October 11, 2024 | 2.062B |
| October 10, 2024 | 1.938B |
| October 09, 2024 | 1.939B |
| October 08, 2024 | 1.922B |
| October 07, 2024 | 1.946B |
| October 04, 2024 | 1.936B |
| October 03, 2024 | 1.896B |
| October 02, 2024 | 1.965B |
| October 01, 2024 | 1.954B |
| September 30, 2024 | 2.073B |
| September 27, 2024 | 2.029B |
| September 26, 2024 | 1.958B |
| September 25, 2024 | 1.909B |
| September 24, 2024 | 1.983B |
| September 23, 2024 | 1.979B |
| September 20, 2024 | 2.102B |
| September 19, 2024 | 2.213B |
| September 18, 2024 | 2.222B |
| September 17, 2024 | 2.246B |
| September 16, 2024 | 2.064B |
| September 13, 2024 | 2.167B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.107B
Minimum
Mar 16 2020
13.83B
Maximum
Jan 14 2021
3.876B
Average
2.970B
Median
Jun 09 2020
Enterprise Value Benchmarks
| Vertex Pharmaceuticals Inc | 109.46B |
| AC Immune SA | 137.84M |
| Addex Therapeutics Ltd | 4.450M |
| NLS Pharmaceutics Ltd | 14.00M |
| Molecular Partners AG | 28.94M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -85.94M |
| Total Expenses (Quarterly) | 110.13M |
| EPS Diluted (Quarterly) | -1.01 |
| Earnings Yield | -6.05% |
| Normalized Earnings Yield | -4.169 |